-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $123

Benzinga·06/16/2026 12:32:15
Listen to the news
Guggenheim analyst Debjit Chattopadhyay initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $123.